Individuals with severe kidney failure, decompensated liver disease, congestive heart failure with fluid overload, non-ketonic hyper-glycemia, or known hypersensitivity to formulation components should not receive glycine
One of which referred me to the UCFS Multiple Sclerosis Center in San Francisco
BPC 157 may have neuroprotective effects, supporting brain function and possibly aiding in neural recovery, although more research is needed
This combination leverages the complementary mechanisms of both peptides to potentially enhance regenerative outcomes
No lethal dose has been established in animal studies, even at dosages many orders of magnitude higher than those used in therapeutic research
No Certificate of Analysis available Prices dramatically below market averages Unclear peptide sequences or synthesis methods Poor or absent storage condition information No established reputation or verifiable reviews Vague claims about purity without documentation Canadian Regulatory Context Health Canada regulates peptides differently than the United States FDA, though both agencies consider most research peptides outside approved pharmaceutical frameworks
00092-0/asset/68240365-3bb7-461d-91f9-d644c6b9c749/main.assets/gr3.jpg)
01053-X/asset/68ad1d8b-bb7e-4ca0-8f89-99384d885ca3/main.assets/gr2.jpg)
